Sr One is a venture capital and private equity firm investing in biotechnology companies that is headquartered in Cambridge, Massachusetts and was founded in 1985 as the sub-organization of GlaxoSmithKline. Sr One has invested over $830 million invested in the biotechnology space.
Sr One invests in pre-clinical, clinical, and commercial stage biotechnology companies. Notable investments made by Sr One include: Atopix, Alios BioPharma, NuPathe, Concert Pharmaceuticals, Gotham Therapeutics, Illuminoss, TP Therapeutics, ProtAffin, CRISPR Therapeutics, Arcellx, Adheron Therapeutics, Pulmocide, Second Genome, Sumprus Biosciences, Propeller, VHsquared, Nimbus Therapeutics, AGTC, and Constellation Pharmaceuticals.
Their exited investments include CRISPR Therapeutics, Progyny, Propeller Health, Genocea Biosciences, Bicycle Therapeutics, Dicerna Pharmaceuticals, Turning Point Therapeutics, ZappRx, Morphic Therapeutic, Translate Bio and Spero Therapeutics.
Timeline
People
David Madden
Advisor
Imogen Mansfield
Employee
Jens Eckstein
Employee
Joyce A Lonergan
Employee
Rehan Mirza
Employee
GlaxoSmithKline
